Ipsen | GenomeWeb

Ipsen

NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.

NEW YORK (GenomeWeb News) – French biotechnology firm Rarecells today announced that Ipsen and Institut Gustave Roussy, has selected its ISET technology for a study into patients with prostate cancer.

The collaboration will leverage Ipsen's broad portfolio of compounds and BioMérieux's diagnostic tests and focus on prostate and breast cancers, neuroendocrine tumors, and pituitary tomors.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

Among these is a deal between Dicerna Pharmaceuticals and Japan's Kyowa Hakko Kirin, which announced this week that they have expanded their drug-development partnership to include work in immunologic and inflammatory diseases.

Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.

The companies will combine Dicerna's Dicer-substrate technology with Ipsen's peptide-based targeting vectors, which they said will allow cell-specific, intracellular delivery of the RNAi molecules.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.